3.40 is like 78% fib retrace.. This is point of reckoning imho.. With Directors buying I guess it will be a diluted rights issue so they can top up further at big discount DYOR
OCC Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
I88 History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
